Overview
Cytokeratin 20 (CK20) is a low-molecular-weight cytokeratin belonging to the intermediate filament family. It shows a restricted expression pattern compared with CK7, which makes it particularly valuable in diagnostic pathology. CK20 is normally expressed in the glandular epithelium of the gastrointestinal tract, urothelium, and Merkel cells.
Because of this limited distribution, Cytokeratin 20 has become an important marker for the detection and identification of metastatic carcinoma cells, especially when used in combination with CK7. CK20 expression helps in determining the primary site of tumors and in differentiating between various epithelial malignancies. CK20
Symptoms
CK20 itself does not produce symptoms. Its clinical significance lies in the diagnosis and prognostication of cancers. Patients evaluated for CK20 expression may present with symptoms related to the underlying malignancy, such as gastrointestinal complaints, urinary symptoms, or skin lesions, depending on the tumor origin. CK20 assists in correlating histopathological findings with the clinical presentation of these canceCauses
CK20 expression is associated with epithelial differentiation in specific tumors. It is commonly expressed in colorectal carcinoma, Merkel cell tumor, pancreatic carcinoma, gastric carcinoma, cholangiocarcinoma, and transitional cell carcinoma.
Due to its restricted range of expression, CK20 is particularly useful for identifying metastatic cancer cells using immunohistochemistry and PCR-based methods. Diffuse CK20 immunoreactivity is typically limited to a few tumor types, including colon cancer, Merkel cell tumor, transitional cell carcinoma, gastric carcinoma, and pancreatic carcinoma. These expression patterns help distinguish primary tumors from metastatic lesions.
Risk Factors
CK20 expression is linked to tumor stage, disease progression, and prognosis in certain malignancies. In urothelial carcinoma of the bladder, CK20 expression is associated with advanced tumor stage (pT4) and poorer prognosis.
In colorectal cancer, the number of CK20-positive circulating tumor cells (pCTCs) correlates with tumor-node-metastasis stage and lymph node involvement. Higher CK20 pCTC counts are directly proportional to increased risk of recurrence, metastasis, and reduced survival. These findings underline the prognostic value of CK20 in advanced disease.
When interpreted in combination with CK7, CK20 significantly enhances risk stratification and diagnostic accuracy in various epithelial tumors.
Prevention
There is no direct prevention related to CK20 expression, as it is a diagnostic and prognostic biomarker rather than a disease. However, accurate laboratory testing and interpretation are essential. CK20 detection is routinely performed using immunohistochemistry on formalin-fixed, paraffin-embedded tissue.
For liquid biopsy applications, RT-PCR is used for highly sensitive detection of CK20-positive cells in blood samples from patients with colorectal and breast cancers. Sample collection includes bone marrow aspiration (minimum 2.5 ml) and peripheral blood collected in EDTA tubes.
Specimens must be stored and transported at ambient temperature and sent to the laboratory within 8 hours to prevent nucleic acid degradation. CK20 typically shows strong and diffuse cytoplasmic staining, with a characteristic dot-like staining pattern seen in Merkel cell carcinoma, Paget’s disease, and sometimes in mucinous colorectal carcinoma.
Internal positive controls include epithelial cells lining the colon or rectum. Proper use of CK20, especially in combination with CK7, plays a major role in the differentiation, prognosis, and clinical management of various tumors.
